NCT03056001View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

November 16, 2021

Study Completion Date

November 15, 2022

Conditions
Soft Tissue Sarcoma, AdultSoft Tissue Sarcoma, Child
Interventions
DRUG

Pembrolizumab

IV infusion on day 1 of each 3 week cycle, at dose of 200 mg

DRUG

Doxorubicin

IV injection on day 1 of each 3 week cycle, starting at dose of 60 mg/m2 (may be escalated to 75 mg/m2 per investigator discretion after Cycle 1)

Trial Locations (1)

28204

Levine Cancer Institute, Charlotte

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Wake Forest University Health Sciences

OTHER

NCT03056001 - Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma | Biotech Hunter | Biotech Hunter